Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2[ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors

This publication has 14 references indexed in Scilit:

• Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer Cells
  Annals of Internal Medicine, 1988
• Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1
  JNCI Journal of the National Cancer Institute, 1988
• The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
  Annals of Internal Medicine, 1987
• Effects of Interleukin-2 on Renal Function in Patients Receiving Immunotherapy for Advanced Cancer
  Annals of Internal Medicine, 1987
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
  The Journal of Immunology, 1985
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
  The Journal of Experimental Medicine, 1982
• Reporting results of cancer treatment
  Cancer, 1981